Scurlock AM, Burks AW, Sicherer SH, et al. - Given that CoFAR (Consortium for Food Allergy Research) investigators earlier described 52-week results from a randomized, controlled trial of peanut EPIT (epicutaneous immunotherapy), observing modest as well as statistically significant induction of desensitization, highest in children ages 4-11 years, researchers herein assessed alterations in efficacy, safety, as well as mechanistic parameters after extended open-label peanut EPIT. Participants were patients with peanut allergy. These participants (4-25 years) were administered 52 weeks of placebo (PLB), Viaskin Peanut 100 mcg (VP100) or 250 mcg (VP250), then crossover to VP250 for placebo (PLB-VP250) and VP100 (VP100-VP250) participants and continuation of therapy for VP250 participants (total = 130 weeks of active EPIT). Findings demonstrated the good tolerability of extended treatment with VP250 and desensitization noted at week 52 persisted between weeks 52 and 130. Treatment success was evident mainly in younger participants with younger age at the start of active treatment as an essential predictor of success.